Search results
Found 250 matches for
The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.
Human challenge trial launches to study immune response to COVID-19
Clinical Trials Coronavirus COVID-19 General
19 April 2021
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Risk of rare blood clotting higher for COVID-19 than for vaccines
Coronavirus COVID-19 Research
15 April 2021
COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.
Alternating vaccines trial expands to include two additional vaccines
Clinical Trials Coronavirus COVID-19 General
14 April 2021
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19
Clinical Trials Coronavirus COVID-19 Research
12 April 2021
Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.
UK and EU regulators conclude benefits of vaccination continue to outweigh the risks
Coronavirus COVID-19 General
7 April 2021
Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
Link between COVID-19 infection and subsequent mental health and neurological conditions found
Coronavirus COVID-19 General Research
7 April 2021
One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.
New national study of long-term impacts of debilitating lung damage from COVID-19
Coronavirus COVID-19 General Research
7 April 2021
A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.
Opportunities for final goodbyes must be prioritised in COVID-19 pandemic
Coronavirus COVID-19 General Research
31 March 2021
Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.
New study shows overwhelming public support for donating vaccines to low-income countries
Coronavirus COVID-19 General Research
31 March 2021
A survey led by Nuffield Department of Population Health's Health Economics Research Centre has found that most people in high-income countries support donating some of their country’s COVID-19 vaccine supplies to low-income nations who would otherwise struggle to gain access.
MRC HIU researchers release cheap, quick COVID-19 antibody test
Coronavirus COVID-19 General Research
29 March 2021
An international research team led by Oxford University scientists has developed a portable test for antibodies that fight the novel coronavirus that causes COVID-19.
New study finds strong immune response following COVID-19 vaccination
Coronavirus COVID-19 General Research
29 March 2021
A new study has found that 99% of people generate a robust immune response against COVID-19 after just one dose of the Pfizer vaccine, and that after two doses levels of protection were even stronger.
University of Oxford to study nasal administration of COVID-19 vaccine
Clinical Trials Coronavirus COVID-19 General
26 March 2021
The University of Oxford is launching a study investigating the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray.
AstraZeneca publish primary analysis from US trial of coronavirus vaccine
Clinical Trials Coronavirus COVID-19 General Research
25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
The RECOVERY Trial: One year on
Coronavirus COVID-19 General Research
23 March 2021
The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial.
COVID-19: how to tackle vaccine hesitancy among BAME groups
Coronavirus COVID-19 General Research
22 March 2021
USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective
Clinical Trials Coronavirus COVID-19 General Research
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
Two doses of vaccine offer same protection from COVID as prior infection, study finds
Coronavirus COVID-19 General Research
15 March 2021
Two doses of either the Pfizer or Oxford-AstraZeneca vaccine offer similar protection against symptomatic SARS-CoV-2 infection to that coming from natural immunity after infection, an ongoing study of healthcare workers has found.
Characterising SARS-CoV-2 genetic diversity and transmission
Coronavirus COVID-19 General Research
9 March 2021
Adaptive mutations of SARS-CoV-2 are rare and unlikely to be transmitted, but when they are transmitted they can have a big impact, finds a new study.
Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal
Awards and Appointments Coronavirus COVID-19 General Innovation Research
5 March 2021
Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.